Where to Find COVID-19 Vaccines

Three easy ways to find vaccines near you:

MIC COVID-19 Vaccine Toolkit

The MIC has developed a COVID-19 vaccine toolkit containing videos, cue cards, social graphics, and more. Use these assets to help spread our message.

Key Things to Know About COVID-19 Vaccines

COVID-19 vaccines are effective at helping protect against severe disease and death from the virus that causes COVID-19. Getting a COVID-19 vaccine is a safer, more reliable way to build protection than getting sick with COVID-19.

Three COVID-19 vaccines are approved or authorized in the United States to prevent COVID-19: Pfizer-BioNTech Bivalent, Moderna Bivalent and Novavax Adjuvanted.

Everyone six months of age and older may be eligible to get a COVID-19 vaccination.

Talk with your healthcare provider to learn more as COVID-19 vaccine and booster recommendations may be updated as CDC continues to monitor the latest COVID-19 data.

What You Need to Know:

  • Most individuals, depending on age, previously vaccinated with a monovalent COVID-19 vaccine who have not yet received a dose of a bivalent vaccine may receive a single dose of a bivalent vaccine. 
  • Most individuals who have already received a single dose of the bivalent vaccine are not currently eligible for another dose. 
  • Individuals 65 years of age and older who have received a single dose of a bivalent vaccine may receive one additional dose at least four months following their initial bivalent dose. 
  • Most individuals with certain kinds of immunocompromise who have received a bivalent COVID-19 vaccine may receive a single additional dose of a bivalent COVID-19 vaccine at least 2 months following a dose of a bivalent COVID-19 vaccine, and additional doses may be administered at the discretion of, and at intervals determined by, their healthcare provider. However, for immunocompromised individuals 6 months through 4 years of age, eligibility for additional doses will depend on the vaccine previously received. 
  • Most unvaccinated individuals may receive a single dose of a bivalent vaccine, rather than multiple doses of the original monovalent mRNA vaccines. 
  • Children 6 months through 5 years of age who are unvaccinated may receive a two-dose series of the Moderna bivalent vaccine (6 months through 5 years of age) OR a three-dose series of the Pfizer-BioNTech bivalent vaccine (6 months through 4 years of age). Children who are 5 years of age may receive two doses of the Moderna bivalent vaccine or a single dose of the Pfizer-BioNTech bivalent vaccine. 
  • Children 6 months through 5 years of age who have received one, two or three doses of a monovalent COVID-19 vaccine may receive a bivalent vaccine, but the number of doses that they receive will depend on the vaccine and their vaccination history.

Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023

FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) met on June 15, 2023, to discuss and make recommendations for SARS-CoV-2 strain(s) for updated COVID-19 vaccines for use in the United States beginning in the fall of 2023.

For the 2023-2024 formulation of the COVID-19 vaccines for use in the U.S. beginning in the fall of 2023, the committee unanimously voted that the vaccine composition be updated to a monovalent COVID-19 vaccine with an XBB-lineage of the Omicron variant. Following discussion of the evidence, the committee expressed a preference for XBB.1.5.

During this meeting, the advisory committee was informed of the manufacturing timelines, they reviewed the available data on the circulation of SARS-CoV-2 virus variants, current vaccine effectiveness, human immunogenicity data of current vaccines against recently circulating virus variants, the antigenic characterization of circulating virus variants, animal immunogenicity data generated by new candidate vaccines expressing or containing updated spike components, and preliminary human immunogenicity data generated by one XBB.1.5 candidate vaccine.

Based on the totality of the evidence, FDA has advised manufacturers who will be updating their COVID-19 vaccines, that they should develop vaccines with a monovalent XBB 1.5 composition.

Travel

Make sure you are up to date with your COVID-19 vaccines before travel. Check your destination’s COVID-19 situation before traveling. Wearing a mask over your nose and mouth is recommended in indoor areas of public transportation (including airplanes) and indoors in U.S. transportation hubs (including airports).

Helpful Links